Imipenem-cilastatin as initial therapy for febrile cancer patients
- PMID: 3532942
- PMCID: PMC180520
- DOI: 10.1128/AAC.30.2.211
Imipenem-cilastatin as initial therapy for febrile cancer patients
Abstract
Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.
Similar articles
-
Imipenem/cilastatin therapy of infections in cancer patients.Cancer. 1987 Jul 15;60(2):255-62. doi: 10.1002/1097-0142(19870715)60:2<255::aid-cncr2820600224>3.0.co;2-l. Cancer. 1987. PMID: 3297282 Clinical Trial.
-
Imipenem/cilastatin as secondary therapy for infections in cancer patients.J Antimicrob Chemother. 1986 Dec;18 Suppl E:161-6. doi: 10.1093/jac/18.supplement_e.161. J Antimicrob Chemother. 1986. PMID: 3469189
-
Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients.Am J Med. 1988 Jul 25;85(1A):17-20. doi: 10.1016/0002-9343(88)90170-2. Am J Med. 1988. PMID: 3400679 Clinical Trial.
-
Imipenem/cilastatin: the first carbapenem antibiotic.Drug Intell Clin Pharm. 1985 Dec;19(12):895-9. Drug Intell Clin Pharm. 1985. PMID: 3910385 Review.
-
The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials.J Clin Pharmacol. 1988 Feb;28(2):120-7. doi: 10.1002/j.1552-4604.1988.tb05735.x. J Clin Pharmacol. 1988. PMID: 3283176 Review.
Cited by
-
Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins.Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):139-45. doi: 10.1007/BF01964446. Eur J Clin Microbiol Infect Dis. 1991. PMID: 2060514 Clinical Trial.
-
Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.Antimicrob Agents Chemother. 1992 Dec;36(12):2816-20. doi: 10.1128/AAC.36.12.2816. Antimicrob Agents Chemother. 1992. PMID: 1482151 Free PMC article. Clinical Trial.
-
Pseudomonas maltophilia infections in neutropenic patients and the use of imipenem.Postgrad Med J. 1990 Dec;66(782):1090. doi: 10.1136/pgmj.66.782.1090. Postgrad Med J. 1990. PMID: 2084668 Free PMC article. No abstract available.
-
Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group.Antimicrob Agents Chemother. 1991 May;35(5):873-8. doi: 10.1128/AAC.35.5.873. Antimicrob Agents Chemother. 1991. PMID: 1854169 Free PMC article. Clinical Trial.
-
Ceftriaxone versus aztreonam plus cefazolin for infections in cancer patients with adequate neutrophil counts.Infection. 1990 May-Jun;18(3):166-9. doi: 10.1007/BF01642106. Infection. 1990. PMID: 2365468 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical